Sheets Smith Wealth Management Has $833,000 Position in Celgene Co. (CELG)

Sheets Smith Wealth Management lowered its position in shares of Celgene Co. (NASDAQ:CELG) by 2.9% in the 4th quarter, HoldingsChannel reports. The fund owned 12,993 shares of the biopharmaceutical company’s stock after selling 385 shares during the quarter. Sheets Smith Wealth Management’s holdings in Celgene were worth $833,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of CELG. Csenge Advisory Group bought a new stake in shares of Celgene during the 3rd quarter valued at $90,000. Atlantic Trust LLC bought a new stake in shares of Celgene during the 2nd quarter valued at $101,000. Moneta Group Investment Advisors LLC grew its position in shares of Celgene by 2,688.6% during the 2nd quarter. Moneta Group Investment Advisors LLC now owns 10,290 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 9,921 shares during the period. Harvest Fund Management Co. Ltd bought a new stake in shares of Celgene during the 3rd quarter valued at $132,000. Finally, City Holding Co. bought a new stake in shares of Celgene during the 2nd quarter valued at $143,000. 72.80% of the stock is owned by institutional investors and hedge funds.

A number of research firms recently weighed in on CELG. Robert W. Baird upgraded shares of Celgene from a “neutral” rating to an “outperform” rating and set a $92.00 target price on the stock in a research note on Friday, January 4th. BidaskClub upgraded shares of Celgene from a “strong sell” rating to a “sell” rating in a research note on Friday, January 4th. ValuEngine upgraded shares of Celgene from a “strong sell” rating to a “sell” rating in a research note on Friday, January 4th. Goldman Sachs Group upgraded shares of Celgene from a “sell” rating to a “neutral” rating and boosted their price target for the stock from $71.00 to $88.00 in a research note on Thursday, January 3rd. Finally, Wells Fargo & Co decreased their price target on shares of Celgene from $90.00 to $84.00 and set a “market perform” rating on the stock in a research note on Thursday, January 3rd. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $110.17.



Celgene stock opened at $87.40 on Friday. Celgene Co. has a twelve month low of $58.59 and a twelve month high of $107.29. The company has a debt-to-equity ratio of 4.06, a quick ratio of 1.99 and a current ratio of 2.13. The stock has a market capitalization of $61.19 billion, a PE ratio of 12.78, a price-to-earnings-growth ratio of 0.46 and a beta of 1.44.

Celgene (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $2.29 EPS for the quarter, beating the consensus estimate of $2.02 by $0.27. The company had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.83 billion. Celgene had a net margin of 19.64% and a return on equity of 108.76%. On average, equities analysts forecast that Celgene Co. will post 7.45 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Sheets Smith Wealth Management Has $833,000 Position in Celgene Co. (CELG)” was first posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://dakotafinancialnews.com/2019/01/12/sheets-smith-wealth-management-has-833000-position-in-celgene-co-celg.html.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

See Also: What is Cost of Capital?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply